NATCO launches BENDIT
Apr 07th 2011
Hyderabad based NATCO Pharma is pleased to announce the commercial launch of its brand - BENDIT - Bendamustine - a novel agent in the treatment of Chronic Lymphocytic Leukemia (CLL), mostly seen in the elderly people.
Bendamustine is a unique hybrid cytotoxic, which is mechanistically distinct from the existing options. Response rates to Bendamustine are reported to be high and durable, and the therapy is seen as a superior and tolerable first line option in the treatment of CLL.
Bendit is the generic version of Treanda, the innovator brand, which is priced at around Rs.86,000 per vial of 100mg. Bendit is aggressively priced at Rs.6,950 per vial of 100mg., in accordance with NATCO'S policy of making available quality medicare at an affordable price.
NATCO is exploring the possibility of introducing this product in international markets as well.